EMA grants orphan drug status to Sanofi’s Efdoralprin Alfa for rare lung disease

Efdoralprin alfa, a recombinant human alpha-1 antitrypsin (AAT)-Fc fusion protein, showed superior efficacy to standard plasma-derived therapy in adults with AATD

GSK’s Exdensur gains FDA nod for severe asthma with just two doses a year

The approval for Exdensur (depemokimab-ulaa) comes on the back of SWIFT-1 and SWIFT-2 Phase III trials

Cipla launches Yurpeak (tirzepatide) for the treatment of obesity and type 2 diabetes in India

Tirzepatide is the first and only dual agonist glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors

Roche launches first rapid point-of-care test for whooping cough

The PCR-based test, delivered via Roche’s cobas liat system, allows results to be obtained during a patient consultation in GP practices and Emergency Rooms

AbbVie’s Atogepant shows breakthrough results for acute migraine relief

Suffering from acute migraine? You may soon bid adieu to the debilitating headache

Cipla opens India's First dedicated lung health diagnostics center in Delhi

Glenmark launches world’s first nebulized triple therapy for COPD

Clinical studies conducted in India demonstrated that this nebulized triple therapy rapidly improves lung function and offers better control of breathlessness

Novartis scores FDA nod for game-changing SMA treatment

Itvisma is a one-time, fixed-dose therapy designed to tackle the genetic root cause of SMA

AstraZeneca to invest $2 billion in Maryland manufacturing expansion

The multibillion-dollar Maryland expansion is part of AstraZeneca’s sweeping $50 billion global investment plan

ALBIS unveils next-gen healthcare materials at COMPAMED 2025

ALBIS will present a selection of advanced materials from its broad healthcare portfolio